Genovis AB (publ.) Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Genovis AB (publ.) (STO:GENO) Third Quarter 2024 Results

Key Financial Results

• Revenue: kr48.5m (up 61% from 3Q 2023).
• Net income: kr13.8m (up 340% from 3Q 2023).
• Profit margin: 28% (up from 10% in 3Q 2023). The increase in margin was driven by higher revenue.
• EPS: kr0.21 (up from kr0.048 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genovis AB (publ.) Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) missed analyst estimates by 80%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Sweden.

Performance of the Swedish Life Sciences industry.

The company's shares are up 17% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Genovis AB (publ.) (1 is potentially serious!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.